Medicare coverage of outpatient ambulatory intravenous antibiotic therapy: a program that pays for itself

Area of Science:

• Infectious Diseases
• Health Economics
• Health Policy

Background:

• Outpatient intravenous (i.v.) antibiotic therapy is safe, effective, and cost-effective for infectious diseases.
• Current Medicare policy restricts coverage for outpatient, self-administered drugs, limiting access to ambulatory i.v. therapy.
• This restriction forces Medicare patients into more expensive inpatient hospital care.

Purpose of the Study:

• To evaluate the financial impact of a new Medicare benefit for ambulatory i.v. antibiotic therapy.
• To test the hypothesis that this benefit could significantly reduce Medicare expenditures for infectious disease treatment.

Main Methods:

• A cost model was developed using clinical literature, expert opinions, and Medicare/medical claims data.
• The model simulated patient care for conditions like pneumonia, osteomyelitis, cellulitis, and endocarditis.
• Analysis focused on potential cost savings over a 5-year period.

Main Results:

• The cost model projects cumulative 5-year savings of nearly $1.5 billion.
• Implementing the proposed Medicare benefit is associated with substantial financial reductions.

Conclusions:

• A new Medicare benefit for ambulatory i.v. antibiotic therapy offers significant cost-saving potential.
• Policymakers should consider adopting this benefit to reduce Medicare expenditures for infectious diseases.